In this video, Mikhail Varshavski, DO, who goes by "Dr. Mike," talks with Christle Guevarra, DO, MS, about her struggle with weight, her journey with GLP-1 drugs, and her career in medicine.
Scripps News on MSN
Eli Lilly seeks FDA approval for pill that maintains weight loss after Wegovy, Zepbound
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping Wegovy or Zepbound injections.
The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...
As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...
Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli Lilly are both developing a new generation of obesity drugs. Eli Lilly and Novo Nordisk - the dominant players ...
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
Novo Nordisk said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, ...
Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...
President Trump launched TrumpRx, a new initiative aiming to slash prescription drug costs by forging direct deals with ...
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback